Fredun Pharmaceuticals discussed its strong Q1 results, reporting a 90% revenue growth to INR228.25 Cr, EBITDA up 93% to INR32.78 Cr, and net profit up 95% to INR13.17 Cr.

The company expects 30-35% blended annual growth for its diverse portfolio, driven by new age brands and capacity expansion.

Its Fredun GX line is expanding into 19 states, targeting 25-35% yearly growth.

The comprehensive pet care platform, Wagr.in, is soft-launched and adding services.

CapEx for the current year is projected at INR30-40 Cr, focused on becoming a large manufacturing unit.

Future margin expansion is anticipated after initial penetration efforts.